<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

December 10, 2020

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

The U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for to be used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Yourway is dedicated to supporting clinical trials for innovative and badly needed drugs like this.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

GCSG 2026 European Knowledge Forum

October 14-15, 2026
Rome, Italy

Media

Articles

Your Clinical Trial Has 99 Problems. Logistics Shouldn’t Be One.

Open chat
Come chat with us!
Hello! How can I help you?